For more than half a century, marijuana has sat near the top of the U.S. government’s list of the most dangerous drugs, officially grouped with heroin and treated as a substance with no accepted medical use and a high risk of abuse. That image has long clashed with the reality on the ground, where nearly every state has quietly built its own medical-marijuana programs, and many have gone even further with legal recreational sales. Now, in a move that both completes and deepens a long-running policy shift, the Trump administration has moved state-licensed medical marijuana into a less restrictive federal category, effectively acknowledging that cannabis occupies a different place in the modern health-care and business landscape than it did in the 1970s.
Under the Controlled Substances Act, Schedule I is reserved for drugs that regulators say have no accepted medical use and a high potential for abuse, making it harder to research, prescribe, or legally operate around them. By contrast, Schedule III drugs are still controlled but are recognized as having legitimate medical applications and somewhat lower abuse risk, which opens the door to more research, clearer regulation, and more normal business treatment. The recent order, signed by Acting U.S. Attorney General Todd Blanche, moves state-licensed medical marijuana from Schedule I to Schedule III, a change that does not legalize the drug nationwide but instead reshapes how it is treated inside the federal system.
This step is the latest chapter in a much older story. Early U.S. policy toward marijuana was shaped by a mix of moral panic, racial prejudice, and limited scientific understanding. The Marihuana Tax Act of 1937 effectively criminalized the drug at the federal level, even though it was not framed as an outright ban, while later decades added layers of federal penalties and restrictions. When Congress passed the Controlled Substances Act in 1970, marijuana was placed in Schedule I over the objections of some government commissions that had urged a more moderate approach, cementing its status as a highly restricted substance even as the debate over its risks and benefits intensified.
For decades, that federal stance remained separated from what was happening in states. In 1996, California became the first to adopt a medical-marijuana program, and over the next three decades, roughly 40 states followed, creating their own licensing systems, patient registries, and safety rules. Even as states expanded access, Congress in 2015 barred the U.S. Department of Justice from using its funds to shut down state-licensed medical-marijuana operations, in effect allowing a patchwork of state-level legality to exist under a federal prohibition that was still technically in force.
The new order marks a clear pivot in that long-running tension between federal law and state practice. By shifting state-licensed medical marijuana to Schedule III, the federal government now recognizes that cannabis has a legitimate medical role, at least in the context of state-approved programs. The move also sets up a faster track for state-licensed producers and distributors to register with the U.S. Drug Enforcement Administration, a step that brings some of the industry’s once-shadowy operations closer to standard pharmaceutical oversight. At the same time, the policy signals that federal regulators do not intend to punish researchers who use state-licensed marijuana in clinical studies, effectively opening doors for more rigorous data on doses, side effects, and long-term outcomes.
From a business and tax perspective, the reclassification is arguably as significant as the policy signal. For years, companies operating in the legal cannabis space faced an unusual tax burden under Section 280E of the U.S. Internal Revenue Code, which blocked ordinary business expense deductions for traffickers in Schedule I or Schedule II drugs, even when those businesses were fully legal under state law. Moving state-licensed medical marijuana into Schedule III could, in practice, allow affected companies to deduct many standard operating costs, improving their after-tax profitability and making their financial statements look more like those of other health-care or regulated-product businesses. This change would not only reshape individual balance sheets but could also influence how mainstream financial institutions, insurers, and investors view an industry that has long sat on the edge of the formal financial system.
The administration has also signaled that this is not the end of the process. Building on an executive order President Trump signed in late 2025, the Justice Department and the U.S. Department of Health and Human Services are now preparing to hold a formal hearing in late June to examine whether marijuana should be reclassified more broadly, beyond just state-licensed medical uses. That next stage will likely test whether the federal government can move toward a more coherent national framework, one that reconciles the widespread state-level acceptance of cannabis with the responsibilities of public-health oversight, workplace safety, and international treaty obligations.
As the federal government finally begins to align its official stance with the reality of state-level medical-marijuana programs, the implications stretch well beyond dispensaries and pharmacies. The change loosens the legal and tax constraints on companies that have long operated in a gray zone, creates new incentives for clinical research, and forces regulators to confront the gap between old assumptions and modern evidence. For a country that first criminalized marijuana in the 1930s, then doubled down on that decision in the 1970s, and then watched states quietly rewrite the rules over the past three decades, this latest shift feels less like a sudden reversal and more like a long-overdue adjustment to a landscape that has already moved on.
